Business Description
Landos Biopharma Inc
NAICS : 541714
SIC : 2833
ISIN : US5150692011
Share Class Description:
LABP: Ordinary SharesDescription
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages. The company's pipeline includes NX-13, LABP-66, LAPB-73, LABP-69. The company's current focus and lead product candidate is NX-13, a novel, oral, gut-selective, NLRX1 agonist.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.84 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 22.6 | |||||
| 3-Year EPS without NRI Growth Rate | 23.2 | |||||
| 3-Year FCF Growth Rate | 18 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 94.84 | |||||
| 9-Day RSI | 94.36 | |||||
| 14-Day RSI | 94.27 | |||||
| 6-1 Month Momentum % | 491.16 | |||||
| 12-1 Month Momentum % | 637.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.09 | |||||
| Quick Ratio | 6.09 | |||||
| Cash Ratio | 6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 7.3 | |||||
| Shareholder Yield % | -19.61 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.2 | |||||
| Price-to-Tangible-Book | 2.2 | |||||
| EV-to-EBIT | 0.2 | |||||
| EV-to-EBITDA | 0.2 | |||||
| EV-to-FCF | 0.22 | |||||
| Price-to-Net-Current-Asset-Value | 2.2 | |||||
| Price-to-Net-Cash | 2.24 | |||||
| Earnings Yield (Greenblatt) % | 500 | |||||
| FCF Yield % | -29.19 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LABP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Landos Biopharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.46 | ||
| Beta | 0.24 | ||
| Volatility % | 241.24 | ||
| 14-Day RSI | 94.27 | ||
| 14-Day ATR ($) | 0.503222 | ||
| 20-Day SMA ($) | 21.637915 | ||
| 12-1 Month Momentum % | 637.93 | ||
| 52-Week Range ($) | 2.5 - 22.84 | ||
| Shares Outstanding (Mil) | 3.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Landos Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Landos Biopharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Landos Biopharma Inc Frequently Asked Questions
What is Landos Biopharma Inc(LABP)'s stock price today?
The current price of LABP is $22.49. The 52 week high of LABP is $22.84 and 52 week low is $2.50.
When is next earnings date of Landos Biopharma Inc(LABP)?
The next earnings date of Landos Biopharma Inc(LABP) is 2024-05-10 Est..
Does Landos Biopharma Inc(LABP) pay dividends? If so, how much?
Landos Biopharma Inc(LABP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers